This controversy may be resolved by the confirmatory IGNYTE-3 trial which is an ongoing randomized phase III trial evaluating RP1 plus nivolumab versus standard-of-care in patients with advanced melanoma who have progressed after prior anti-PD-1 and anti-CTLA-4 therapy [42]. Here, PDCD1 is linked to melanoma.